ArticlePDF AvailableLiterature Review

Neuroprotective Actions of Dietary Choline

MDPI
Nutrients
Authors:

Abstract and Figures

Choline is an essential nutrient for humans. It is a precursor of membrane phospholipids (e.g., phosphatidylcholine (PC)), the neurotransmitter acetylcholine, and via betaine, the methyl group donor S-adenosylmethionine. High choline intake during gestation and early postnatal development in rat and mouse models improves cognitive function in adulthood, prevents age-related memory decline, and protects the brain from the neuropathological changes associated with Alzheimer’s disease (AD), and neurological damage associated with epilepsy, fetal alcohol syndrome, and inherited conditions such as Down and Rett syndromes. These effects of choline are correlated with modifications in histone and DNA methylation in brain, and with alterations in the expression of genes that encode proteins important for learning and memory processing, suggesting a possible epigenomic mechanism of action. Dietary choline intake in the adult may also influence cognitive function via an effect on PC containing eicosapentaenoic and docosahexaenoic acids; polyunsaturated species of PC whose levels are reduced in brains from AD patients, and is associated with higher memory performance, and resistance to cognitive decline.
PC-DHA levels depend on nutrition, liver and brain synthesis by PEMT and transport of LPC-DHA across the blood-brain barrier catalyzed by MFSD2A. Plasma PC levels and PC FA molecular species (e.g., PC-DHA) depend on hepatic PC metabolism, the dietary supply of choline and n-3 FA, including DHA, and PC and LPC flux between plasma and tissues (e.g., brain). Hepatic PEMT activity is high and the liver produces large amounts of PC-DHA by methylating PE for the needs of the entire organism. This PC-DHA is secreted by the liver into the circulation as a component of lipoproteins. Brain PEMT activity is relatively low and neuronal and glial PEMT produces PC-DHA to sustain local membranes. PC synthesis by PEMT requires three molecules of SAM that is synthesized from the amino acid, methionine. In addition to PC, PEMT generates SAH that is hydrolyzed to homocysteine. The latter can be converted back to methionine by two pathways: one catalyzed by betaine:homocysteine S-methyltransferase (BHMT) and another catalyzed by vitamin B12-requiring 5-methyltetrahydrofolate-homocysteine S-methyltransferase (MTR), in which methyltetrahydrofolate is used as a methyl donor. Betaine is the product of enzymatic oxidation of choline. Thus, dietary choline is used to produce PC directly and to convert homocysteine to methionine and subsequently to SAM. In this fashion the methyl groups derived from dietary choline can be utilized by PEMT to generate PC-DHA. Recent evidence indicates that the main source of brain DHA is LPC-DHA—the circulating deacylated metabolite of PC-DHA. The transport of LPC-DHA from plasma to the brain is catalyzed by MFSD2A. The blue arrows indicate flux and the black arrows represent enzymatic pathways. Protein names are in red. Dietary DHA is primarily stored in PE in tissues and only a small fraction is incorporated directly into PC. Homocysteine can also be converted to cysteine via cystathionine in a transsulfuration pathway that includes two vitamin B6-requiring enzymes, CBS and CTH. Abbreviations: BHMT, betaine:homocysteine S-methyltransferase; CBS, cystathionine-beta-synthase; CTH, cystathionine gamma-lyase; DHA, docosahexaenoic acid; FA, fatty acid; LPC, lysophosphatidylcholine; MFSD2A, major facilitator superfamily domain containing 2a; MTR, 5-methyltetrahydrofolate-homocysteine S-methyltransferase; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PEMT, phosphatidylethanolamine N-methyltransferase; SAH, S-adenosylhomocysteine; SAM, S-adenosylmethionine.
… 
This content is subject to copyright.
nutrients
Review
Neuroprotective Actions of Dietary Choline
Jan Krzysztof Blusztajn *, Barbara E. Slack and Tiffany J. Mellott
Department of Pathology and Laboratory Medicine, Boston University School of Medicine,
72 East Concord Street, Boston, MA 02118, USA; bslack@bu.edu (B.E.S.); tmellott@bu.edu (T.J.M.)
*Correspondence: jbluszta@bu.edu
Received: 20 June 2017; Accepted: 25 July 2017; Published: 28 July 2017
Abstract:
Choline is an essential nutrient for humans. It is a precursor of membrane phospholipids
(e.g., phosphatidylcholine (PC)), the neurotransmitter acetylcholine, and via betaine, the methyl group
donor S-adenosylmethionine. High choline intake during gestation and early postnatal development
in rat and mouse models improves cognitive function in adulthood, prevents age-related memory
decline, and protects the brain from the neuropathological changes associated with Alzheimer’s
disease (AD), and neurological damage associated with epilepsy, fetal alcohol syndrome, and
inherited conditions such as Down and Rett syndromes. These effects of choline are correlated
with modifications in histone and DNA methylation in brain, and with alterations in the expression
of genes that encode proteins important for learning and memory processing, suggesting a possible
epigenomic mechanism of action. Dietary choline intake in the adult may also influence cognitive
function via an effect on PC containing eicosapentaenoic and docosahexaenoic acids; polyunsaturated
species of PC whose levels are reduced in brains from AD patients, and is associated with higher
memory performance, and resistance to cognitive decline.
Keywords:
Alzheimer’s disease; autism; brain; choline; epilepsy; DNA methylation; memory;
nutrition; pregnancy
1. Choline: An Essential Nutrient for Humans
Choline is an essential nutrient; that is, together with essential amino acids, fatty acids, vitamins and
minerals, it must be obtained from the diet to maintain health [
1
]. Because choline is present in many foods,
a variety of diets can satisfy the need for this nutrient. For the purposes of estimating choline intake by
people, researchers use a database available at the US Department of Agriculture web site that lists dietary
compounds that contain the choline moiety (i.e., free choline, glycerophosphocholine, phosphocholine,
phosphatidylcholine, sphingomyelin and betaine—a metabolite of choline) [
2
]. Because all of those
compounds provide bioavailable choline, studies on choline intake generally refer to the total dietary
choline. Adequate Intake (AI) recommendations, issued by the Food and Nutrition Board of the
Institute of Medicine of the National Academy of Sciences, call for an average daily intake of 7.5 mg of
choline per kg of body weight, but are higher during pregnancy and lactation [
1
], given the needs of the
fetus and nursing baby [
3
5
]. Reported pathological effects of low choline consumption include liver
dysfunction in adult men [
6
], muscle damage [
7
], and apoptotic death of lymphocytes [
8
]. Moreover,
higher consumption of choline or betaine (an oxidized choline metabolite and a methyl group donor)
in adults is associated with reduced risk of some cancers [913] (reviewed in [14]).
Choline has been shown to exert neuroprotective effects in both animal and human studies.
High choline intake during the perinatal period is neuroprotective in a variety of animal models of
neuronal dysfunction, including that resulting from aging [
15
17
], seizures [
18
21
], prenatal alcohol
exposure [
22
27
] and the genetic disorders Rett syndrome [
28
31
] and Down syndrome [
32
38
].
Dietary supplementation with choline-containing compounds, alone or in combination with other
methyl donors such as folate and vitamin B12, was also found to ameliorate neurological impairments
Nutrients 2017,9, 815; doi:10.3390/nu9080815 www.mdpi.com/journal/nutrients
Nutrients 2017,9, 815 2 of 23
in animal models of stroke [
39
], and ischemia [
40
]. Moreover, high choline consumption during
pregnancy correlated with reduced risk of neural tube defects in humans [
41
,
42
]. This association
was less robust in more recent studies—possibly as a result of the addition of choline to vitamin
supplements routinely taken by pregnant women, and variations in total daily caloric intake and
reported ranges of choline consumption, in the different studies [
43
,
44
]. Dietary intake of choline in
adult human subjects has been shown to correlate with cognitive function [
45
], and treatment with
certain choline-containing compounds showed a limited tendency to reduce cognitive impairment in
human vascular dementias in small clinical trials [46].
In this review, we summarize the results of studies in animal models and humans on the
effects of perinatal choline nutrition on brain development, on cognitive function in the adult, and
on the progression of several neurodegenerative diseases. We also discuss emerging evidence for
neuroprotective effects of dietary choline consumption during adulthood. While we focus on choline,
it is important to recognize that other nutrients such as folate, vitamin B12 and vitamin B6, influence
the metabolism of choline, and their availability may modify the requirements for choline.
2. Choline Nutrition during Development and Cognitive Function
2.1. Protection against Age-Related Memory Decline and Advancement of Hippocampal Development
In rats, high maternal choline consumption at specific times during pregnancy (Embryonic
Days 11–17) enhances cognitive ability of the offspring throughout life [
15
,
17
,
47
53
]. One important
developmental benchmark, the ability to navigate using relational cues in a Morris water maze,
was found to occur three days earlier in prenatally choline-supplemented rats [
51
]. The acquisition
of this ability is thought to signal the onset of hippocampal function [
54
]. Thus, prenatal choline
supplementation causes an approximately three-day advancement in hippocampal development.
While it is not possible to conduct a similar, well controlled study in humans, data obtained by project
Viva in Massachusetts show that maternal choline intake within the AI range during pregnancy was
associated with better memory function in children at seven years of age as compared to children of
mothers whose consumption was approximately 50% of the AI levels [
55
] (Figure 1). Thus, in humans,
as in animal models, higher gestational consumption of choline has long-term positive effects on
cognition during childhood. However, it is not yet known if these effects persist into adulthood and
old age in humans. Using a rat model, Meck et al. [
17
] altered choline availability to rats during seven
timeframes spanning Embryonic Day (E) 6 through Postnatal Day (P) 75 and examined spatial memory
ability in the perinatally-treated adults. Two sensitive periods were identified, E12–17 and P16–30,
during which choline supplementation facilitated spatial memory. Moreover, choline supplementation
during E12–17 only, prevented the memory decline normally observed in aged (26 months old) rats [
17
].
Nutrients 2017, 9, 815 2 of 22
methyl donors such as folate and vitamin B12, was also found to ameliorate neurological
impairments in animal models of stroke [39], and ischemia [40]. Moreover, high choline consumption
during pregnancy correlated with reduced risk of neural tube defects in humans [41,42]. This
association was less robust in more recent studies—possibly as a result of the addition of choline to
vitamin supplements routinely taken by pregnant women, and variations in total daily caloric intake
and reported ranges of choline consumption, in the different studies [43,44]. Dietary intake of choline
in adult human subjects has been shown to correlate with cognitive function [45], and treatment with
certain choline-containing compounds showed a limited tendency to reduce cognitive impairment in
human vascular dementias in small clinical trials [46].
In this review, we summarize the results of studies in animal models and humans on the effects
of perinatal choline nutrition on brain development, on cognitive function in the adult, and on the
progression of several neurodegenerative diseases. We also discuss emerging evidence for
neuroprotective effects of dietary choline consumption during adulthood. While we focus on choline,
it is important to recognize that other nutrients such as folate, vitamin B12 and vitamin B6, influence
the metabolism of choline, and their availability may modify the requirements for choline.
2. Choline Nutrition during Development and Cognitive Function
2.1. Protection against Age-Related Memory Decline and Advancement of Hippocampal Development
In rats, high maternal choline consumption at specific times during pregnancy (Embryonic Days
1117) enhances cognitive ability of the offspring throughout life [15,17,47–53]. One important
developmental benchmark, the ability to navigate using relational cues in a Morris water maze, was
found to occur three days earlier in prenatally choline-supplemented rats [51]. The acquisition of this
ability is thought to signal the onset of hippocampal function [54]. Thus, prenatal choline
supplementation causes an approximately three-day advancement in hippocampal development.
While it is not possible to conduct a similar, well controlled study in humans, data obtained by project
Viva in Massachusetts show that maternal choline intake within the AI range during pregnancy was
associated with better memory function in children at seven years of age as compared to children of
mothers whose consumption was approximately 50% of the AI levels [55] (Figure 1). Thus, in
humans, as in animal models, higher gestational consumption of choline has long-term positive
effects on cognition during childhood. However, it is not yet known if these effects persist into
adulthood and old age in humans. Using a rat model, Meck et al. [17] altered choline availability to
rats during seven timeframes spanning Embryonic Day (E) 6 through Postnatal Day (P) 75 and
examined spatial memory ability in the perinatally-treated adults. Two sensitive periods were
identified, E12–17 and P16–30, during which choline supplementation facilitated spatial memory.
Moreover, choline supplementation during E12–17 only, prevented the memory decline normally
observed in aged (26 months old) rats [17].
Adequate Intake
for pregnant
women
-0.8
-0.4
0
0.4
0.8
1.2
1.6
2
2.4
200 300 400 500 600
Mean difference in WRAML2
Second trimester daily choline intake, mg
Figure 1.
Relationship between intake of choline during the second trimester of pregnancy and
offspring visual memory assessed by Wide Range Assessment of Memory and Learning, Second Edition
(WRAML2). The top quartile choline intake was associated with a child WRAML2 score 1.4 points
higher than the bottom quartile (P-trend = 0.003). Figure created from data in [55].
Nutrients 2017,9, 815 3 of 23
2.2. Cellular, Transcriptomic, Proteomic and Epigenetic Correlates of the Neuroprotective Action of Choline
During fetal development, maternal choline deficiency inhibits hippocampal precursor cell
proliferation and stimulates apoptosis in the hippocampus [
56
], whereas gestational choline
supplementation stimulates hippocampal cell division [
57
]. In the adult, neurogenesis in the
dentate gyrus of the hippocampus, a process that occurs throughout life [
58
60
], is enhanced by
prenatal choline supplementation, and impaired by prenatal choline deficiency [
20
,
61
,
62
]. This effect
on adult neurogenesis was associated with increased hippocampal concentrations of the trophic
factors nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), insulin-like growth
factor 2 (IGF2), and vascular endothelial growth factor (VEGF) [
20
,
61
65
], increased size of basal
forebrain cholinergic neurons [
66
]—cells required for normal cognitive function [
67
,
68
]—and elevated
acetylcholine synthesis and release from these neurons [
17
,
65
,
69
]. Prenatal choline supplementation
increased the phosphorylation of mitogen-activated protein kinase (MAPK) and 3
0
,5
0
-cyclic adenosine
monophosphate (cAMP) response element binding protein (CREB) in response to activation of
glutamate receptors in hippocampus, [
51
]. The MAPK signaling cascade, and its downstream targets
including CREB, are central players in the processes underlying synaptic plasticity, and learning
and memory [
70
]. The induction in hippocampus of long term potentiation, an electrophysiological
correlate of synaptic plasticity [
71
], was similarly sensitive to prenatal choline availability [
49
,
72
].
Gene expression analysis identified 530 hippocampal and 815 cerebral cortical mRNA species whose
levels were affected by prenatal choline status [
64
]. The protein products of a subset of these genes,
including calcium/calmodulin-dependent kinase 1 and IGF2, participate in signaling pathways
involved in memory processes and thus may contribute to the observed choline-induced changes in
cognitive performance (reviewed in [73]).
Advances in the field of epigenetics have provided a framework to explain how heritable changes
in gene expression patterns may be propagated during development and throughout adulthood
without altering the primary DNA sequence. The methylation of CpG sequences within the regulatory
elements of genes changes their expression via an interaction with a complex network of proteins,
including transcription factors [
74
]. Following DNA replication, the unmethylated daughter strand
in hemimethylated DNA is symmetrically methylated by the enzyme DNA methyltransferase 1
(DNMT1) [
75
], thus recapitulating the parent methylation pattern in the daughter cells. The process of
DNA methylation is dynamic [
76
] and responsive to changes in the environment, including alterations
in nutrient availability. In particular, DNA methylation is modulated by the availability of nutrients
that serve as methyl group donors and cofactors, such as choline, betaine, methionine, folic acid and
vitamin B12, via their influence on tissue levels of S-adenosylmethionine (SAM) (the methyl group
donor for most enzymatic methylation reactions) (see [
77
] for a review).
Kovacheva et al. [78]
evaluated
DNA methylation parameters in liver and cerebral cortex on E17 in rats exposed in utero to varying
amounts of choline (via the diet supplied to pregnant dams) beginning on E11. The investigators
focused on the differentially methylated region 2 (DMR2) of the Igf2 gene, which undergoes a dramatic
change in methylation status during development [
79
]. DMR2 methylation was increased in
choline-deficient embryos, as compared to the control and choline-supplemented rats, and was
accompanied by a compensatory increase in the expression of the maintenance DNA methylase Dnmt1.
Because DNA methylation is highly dynamic in adult brain and may modulate the expression of
genes involved in the regulation of synaptic plasticity [8084] and learning and memory [8596], it is
possible that dietary availability of methyl donors such as choline in the adult will also prove to be an
important determinant of cognitive function.
2.3. Neuroprotective Actions of Perinatal Choline in Animal Models of Disease
2.3.1. Epilepsy
Status epilepticus, a period of prolonged seizures, is a neurological condition that produces multiple
degenerative and regenerative changes in the hippocampus [
97
]. These changes are accompanied by
Nutrients 2017,9, 815 4 of 23
cognitive deficits in hippocampal-dependent tasks [
97
]. Several studies tested the effects of high choline
intake in rat models of chemically-evoked epilepsy. In pilocarpine- [
18
] and kainic acid- [
19
,
21
] induced
status epilepticus, prenatal choline supplementation attenuated the deficits in visual-spatial memory.
In addition, these protective actions of choline were accompanied by a decrease in seizure-induced
hippocampal neurodegeneration, and a reduction in compensatory proliferation of cells within the
dentate gyrus [
98
]. Moreover, choline supplementation prevented hippocampal loss of GAD65
mRNA [
98
], which encodes a form of the
γ
-aminobutyric acid (GABA)-synthesizing enzyme,
glutamic acid decarboxylase, that is localized to the nerve terminals. As in the other rodent
models [20,29,30,61,65,98,99]
, prior to seizures choline supplementation also increased the levels
of several trophic factors in the hippocampus: specifically, NGF, BDNF and IGF1, indicating that
this nutritional treatment may establish a neuroprotective hippocampal milieu that attenuates
the neuropathological response to and/or helps facilitate recovery from seizures to protect
cognitive function.
2.3.2. Down Syndrome
Down syndrome, a common form of mental retardation, affects approximately 1 in 700 births in
the United States [
100
]. The disorder is caused by trisomy of the whole or a part of chromosome 21, and
the resulting increase in expression of the genes encoded on the extra chromosome [
101
]. Strupp and
colleagues [3238] used a mouse model of Down syndrome (Ts65Dn mice) to test the hypothesis that
choline supplementation from conception to weaning could prevent some of the neurological and
cognitive deficits observed in these mice. The genome of Ts65Dn mice was engineered to carry a third
copy of the distal region of mouse chromosome 16, which contains approximately 94 genes orthologous
to the Down syndrome critical region of the human chromosome 21 [
102
]. The adult offspring of
choline-supplemented Ts65Dn dams performed significantly better than control Ts65Dn mice in
several visual attention tasks [
32
,
35
,
36
]. In some of these tasks, the choline-supplemented Ts65Dn
mice did not differ from the wild type controls [32]. The improvement in spatial cognition correlated
with normalization of hippocampal neurogenesis in choline-supplemented Ts65Dn mice [
35
]. It is
interesting to note that a number of genes on chromosome 21 are involved in epigenetic mechanisms,
including those encoding the DNA methyltransferase-like protein DNMT3L [
101
], which is required
for the establishment of maternal genomic imprints [
103
], and also stimulates de novo methylation
by DNMT3A [
104
]. In frontal cortex neurons purified from Down syndrome patients and controls,
272 genes showed differential methylation of CpG islands; the majority of which were hypermethylated
in Down syndrome relative to controls [
105
,
106
]. An earlier report demonstrated that global DNA
methylation, measured at E17, was reduced in frontal cortex of perinatally choline-supplemented
rats relative to control and choline deficient embryos, and this was reflected in a significant reduction
in mRNA levels of the Dnmt3l and Dnmt3a [
78
] These observations raise the possibility that choline
supplementation in Down syndrome models may improve cognitive function in part by opposing the
hypermethylation that otherwise occurs in neurons of these animals.
2.3.3. Rett Syndrome
Rett syndrome is a genetic neurological disorder of childhood that represents a common
(approximately 1 in 10,000 births) form of mental retardation and almost exclusively affects girls [
31
].
It is usually caused by a mutation in the X chromosome-linked methyl-CpG-binding protein 2 (Mecp2)
gene encoding a protein with possible roles in gene transcription, chromatin organization, alternative
splicing, and miRNA processing [
107
]. Several mouse models with inactivating mutations of Mecp2
have been developed. These mice resemble the human disease in that they are apparently normal at
birth, but develop severe neurological symptoms within weeks. In a series of studies, Berger-Sweeney
and colleagues tested the effects of perinatal choline supplementation in two mouse models of Rett
syndrome [
28
30
,
108
,
109
]. Rett syndrome model mice were supplemented with choline or saccharine
(controls) via the mothers’ milk from birth to weaning. Choline supplementation improved motor
Nutrients 2017,9, 815 5 of 23
coordination and locomotor activity of Mecp2-null males, and grip strength in females, but did not alter
cognitive deficits in either sex [
28
]. These improvements in locomotor function were accompanied by
increases in total brain volume in females, and in cerebellar volume in males [
108
]. Postnatal choline
supplementation increased striatal NGF expression in both wild type and Mecp2 null mice [
29
] and
increased the brain levels of N-acetyl aspartate, a marker of neuronal integrity, in nuclear magnetic
resonance spectroscopy assays [
109
]. These results are consistent with an effect of choline on enhanced
neuronal proliferation and survival in mutant mice. In mice with a different Mecp2 mutation, early
postnatal choline treatment prevented deficits in locomotor activity [
30
], and restored the activity of the
acetylcholine-synthesizing enzyme, choline acetyltransferase (CHAT), in the striatum. In both mouse
models, choline supplementation increased mRNA expression of NGF and BDNF in the cerebral cortex
and hippocampus [
30
,
31
]. Taken together, these data suggest that nutritional supplementation with
choline may improve neuronal function in Rett syndrome patients and thus constitutes a potential
therapy for this disease.
2.3.4. Schizophrenia
To evaluate the possibility that perinatal choline treatment could be useful in preventing certain
psychiatric disorders, Stevens et al. [
110
] studied the effects of choline supplementation in the
DBA/2 mouse strain, which is extensively used as a model of schizophrenia [
111
]—a disease with
60–80% heritability [
112
,
113
]. These mice resemble human schizophrenia patients in that they show
reduced levels of hippocampal
α
7 nicotinic receptors, and deficits in sensory inhibition in response
to repeated auditory stimuli [
114
]. DBA/2 dams were placed on control or choline-supplemented
diets from mating until weaning. The offspring of dams maintained on the control diet displayed the
characteristic abnormality in sensory processing that is also present in patients with schizophrenia,
whereas prenatally choline-supplemented mice exhibited a normal sensory processing phenotype [
110
],
suggesting that this nutritional treatment may reduce the risk of schizophrenia. This effect of choline
was not seen in DBA/2 mice with one or zero copies of the
α
7 nicotinic receptor [
114
], suggesting that
perinatal choline exerts its effect on sensory processing through an action on this receptor.
2.3.5. Alzheimer ’s Disease
Mellott et al. [
62
] used a mouse model of AD to examine the effects of choline supplementation
from conception to weaning on AD pathology. This APPswe/PS1dE9 (APP.PS1; MGI ID: 3524957) AD
model mouse strain was engineered to express murine App with the human A
β
amino acid sequence
harboring mutations that cause a familial form of AD (the Swedish mutation APPK595N/M596L;
APPswe) together with a mutated form of PSEN1 (PS1 with exon 9 deleted; PS1dE9) [
115
]. Though no
model of AD fully recapitulates the human disease [
116
], APP.PS1 mice are characterized by: (1) high
production of amyloid A
β
peptides in brain and accumulation of amyloid plaques by 4–6 months
of age [
117
]; (2) cognitive impairments [
118
122
]; (3) cholinergic defects [
123
128
]; and (4) evidence
of abnormal methylation of several genes [
129
]. Perinatal choline supplementation significantly
reduced the average number of Aβ42 plaques in both 9- and 12-month old APP.PS1 female and male
mice. While the number of A
β
42 plaques increased with age in the control APP.PS1 mice, the plaque
number was more stable in choline-supplemented mice, suggesting that A
β
42 synthesis, clearance,
and/or aggregation may be altered in these mice to prevent additional plaque formation. A decline
in cholinergic function and diminished expression of the cholinergic marker, CHAT, is apparent in
aged humans and animals [
130
132
], in patients with Alzheimer’s disease (AD) [
133
136
], and in
animal models of AD [
118
,
123
128
,
135
,
137
]. Thus, it has been postulated that abnormal cholinergic
neurotransmission, due to dysfunction and/or degeneration of the septo-hippocampal cholinergic
system, contributes to the memory deficits seen in advanced age and in AD [
131
,
135
,
136
]. At 9- and
12-months, CHAT protein levels were significantly decreased in the APP.PS1 female and male mice
from the control group. Perinatal choline supplementation prevented this decrease, suggesting that
choline supplementation may rescue cholinergic function in AD mice. APP.PS1 mice were also
Nutrients 2017,9, 815 6 of 23
characterized by hippocampal gliosis [
128
,
137
139
]. This gliosis was nearly eliminated by perinatal
choline supplementation. Given that activation of glial cells in AD and in AD mouse models may be
initiated by A
β
peptides [
140
], it is possible that reduced gliosis in perinatally choline-supplemented
APP.PS1 mice is secondary to the amelioration of the amyloidosis seen in these animals although it
is also possible that high choline intake during development may have long-term anti-inflammatory
actions in brain. While this study used an AD model caused by genes mutated in the familial human
disease, the vast majority of AD cases are sporadic, with no known causes, and even though AD
prevalence is alarming, affecting over 30% of individuals over 85 years of age [
141
], the disease does
not appear to be an inevitable result of aging. Some of the factors that prevent or forestall AD may be
genetic; e.g., non-carriers of the APOE
ε
4 allele [
142
145
] or individuals who inherit the rare APP A673T
allele [
146
] may be somewhat protected. The study by Mellott et al. [
62
] suggests that vulnerability to
AD may be modified by early-life nutrition.
2.3.6. Autism Spectrum Disorder
Autism spectrum disorder (ASD) is a heterogeneous group of developmental conditions
characterized by deficient social interactions, deficits in verbal and nonverbal communication,
stereotyped, repetitive patterns of behaviors and interests, and cognitive inflexibility in childhood,
frequently continuing into adolescence and adulthood [
147
151
]. ASD has high heritability and genetic
studies identified multiple loci that may increase the risk of ASD [
152
]. However, ASD is not a simple
genetic disorder and environmental factors such as maternal nutrition during the periconceptual
period, and throughout pregnancy and nursing, may contribute to its etiology [
153
,
154
]. While autism
may be uniquely human, animal models have been developed to mimic some of the components
of the disorder. The inbred BTBR T+Itpr3tf/J mice display autism-like behavioral phenotypes, with
deficits in reciprocal social interactions [
155
,
156
], impaired communication, and repetitive behaviors,
as compared with the high sociability and low self-grooming of the reference strain C57BL/6J
(B6) [
157
160
].
Langley et al. [161]
demonstrated that maternal dietary choline supplementation in
BTBR mice during pregnancy and lactation alleviated anxiety-like behaviors and improved deficits
in social behavior in adolescent and adult progeny. Interestingly, the behavioral phenotype-related
genetic quantitative trait loci in BTBR mice contain genes associated with cholinergic neurotransmission
(Chrna3,Chrna5, and Chrnb4), choline (Pcyt1b,Chpt1,Pld1, and Ppap2c) and folate metabolism (Mthfd1,
Mthfs, and Slc19a1), as well as DNA methylation (Dnmt3l and Mecp2). Note that the expression of
Dnmt3l was modulated by choline availability in another study [
78
], and that mutations in MECP2
cause Rett syndrome (see above). Overall, the results suggested that high choline intake during early
development can prevent or reduce deficits in social behavior and anxiety in an autistic mouse model.
2.4. Neuroprotective Effects of Choline Intake in Adults: Implications for Cognitive Aging and Alzheimer’s Disease
Despite choline’s recently acquired status as an essential nutrient [
1
], and its presence in many
foods [
2
], at least 75% of American adults consume less than the recommended Adequate Intake
levels (see above) [
9
,
45
,
73
,
162
,
163
]). A recent National Health and Nutrition Examination Survey
(NHANES) found that only 4% of men and 2% of women over the age of 71 years meet the AI
value [
164
]. This was also found to be the case in a report from the Framingham Heart Study (FHS)
Offspring Cohort (FHS Generation 2), which measured cognitive performance and dietary choline
intake in 1391 dementia-free subjects (age 61
±
9 SD). Approximately 75% of the subjects in this
study consumed less than the recommended AI levels of choline [
45
], as estimated using a Food
Frequency Questionnaire in which participants reported on which foods they had eaten for the prior
12-month period.
Concurrent choline intake was positively correlated with the performance of subjects on verbal
and visual memory tasks (Figure 2) [
45
], and inversely correlated with white-matter hyperintensity
volume, a brain magnetic resonance imaging measurement that is associated with impaired cognitive
function and Alzheimer’s disease [45].
Nutrients 2017,9, 815 7 of 23
Nutrients 2017, 9, 815 7 of 22
volume, a brain magnetic resonance imaging measurement that is associated with impaired cognitive
function and Alzheimer’s disease [45].
Figure 2. Dose–response relationship between the average daily choline intake and verbal and visual
memory performance in non-demented adults. Red lines indicate 95% confidence interval. Figure
created from data in [45].
One possible explanation for the effect of concurrent choline intake on cognition in adults lies in
its function as a precursor of the phospholipid phosphatidylcholine (PC), a major constituent of all
biological membranes, including those in neurons and glial cells. Evidence that phospholipid
metabolism is abnormal in AD originated with postmortem brain sample studies dating to the 1980s
and 1990s [165–168] which showed reduced levels of PC and phosphatidylethanolamine (PE) and
increased levels of their metabolites, glycerophosphocholine and glycerophosphoethanolamine,
respectively, in the cerebral cortex of AD patients as compared to age-matched controls and to
patients with Down syndrome, Parkinson’s disease and Huntington’s disease [167,168]. These data,
and additional evidence that brain regions generally free of plaques and tangles, such as the caudate
and the cerebellum, are similarly affected [167], led to the hypothesis that the phospholipid defect is
specific to AD and widespread within the brain. A large body of evidence, reported since that time,
is consistent with this concept (e.g., [169176]). Moreover, there is a dramatic and specific reduction
in molecular species of PC containing docosahexaenoic acid [DHA, 22:6n-3] (PC-DHA) levels in the
temporal cortex gray matter of AD patients as compared to controls [177]. The advent of metabolomic
techniques that permit untargeted large-scale analyses of hundreds of compounds combined with
the intense need to discover plasma biomarkers for AD resulted in the surprising finding that lipid
abnormalities in AD are not confined to the brain but are also evident in the peripheral blood plasma
[176,178185], suggesting that a blood lipidomic biomarker can be developed for prodromal AD
[176,178183,186,187], and importantly, that a lipid defect might be a driver of this disease. In
particular, the plasma concentrations of PC species with 5 and 6 double bonds are consistently
Figure 2.
Dose–response relationship between the average daily choline intake and verbal and
visual memory performance in non-demented adults. Red lines indicate 95% confidence interval.
Figure created from data in [45].
One possible explanation for the effect of concurrent choline intake on cognition in adults lies
in its function as a precursor of the phospholipid phosphatidylcholine (PC), a major constituent of
all biological membranes, including those in neurons and glial cells. Evidence that phospholipid
metabolism is abnormal in AD originated with postmortem brain sample studies dating to the 1980s and
1990s [
165
168
] which showed reduced levels of PC and phosphatidylethanolamine (PE) and increased
levels of their metabolites, glycerophosphocholine and glycerophosphoethanolamine, respectively,
in the cerebral cortex of AD patients as compared to age-matched controls and to patients with
Down syndrome, Parkinson’s disease and Huntington’s disease [
167
,
168
]. These data, and additional
evidence that brain regions generally free of plaques and tangles, such as the caudate and the
cerebellum, are similarly affected [
167
], led to the hypothesis that the phospholipid defect is specific to
AD and widespread within the brain. A large body of evidence, reported since that time, is consistent
with this concept (e.g., [
169
176
]). Moreover, there is a dramatic and specific reduction in molecular
species of PC containing docosahexaenoic acid [DHA, 22:6n-3] (PC-DHA) levels in the temporal cortex
gray matter of AD patients as compared to controls [
177
]. The advent of metabolomic techniques that
permit untargeted large-scale analyses of hundreds of compounds combined with the intense need to
discover plasma biomarkers for AD resulted in the surprising finding that lipid abnormalities in AD are
not confined to the brain but are also evident in the peripheral blood plasma [
176
,
178
185
], suggesting
that a blood lipidomic biomarker can be developed for prodromal AD [
176
,
178
183
,
186
,
187
], and
importantly, that a lipid defect might be a driver of this disease. In particular, the plasma concentrations
of PC species with 5 and 6 double bonds are consistently reported as reduced in prodromal and/or
frank AD [
178
,
181
183
,
186
,
188
]. Data obtained by studies of erythrocyte membrane lipids further
support these notions. Because erythrocytes live for an average of 120 days, their lipid profiles reflect
Nutrients 2017,9, 815 8 of 23
whole body lipid metabolism over several months [
189
,
190
] as opposed to the snapshot view obtained
from a plasma assay. In a study by Selley [
191
], erythrocytes from AD patients had reductions in
concentrations of PC of 23% and of PC-DHA of 60% as compared to controls. Moreover, lower levels
of erythrocyte phospholipid n-3 fatty acid (eicosapentaenoic [EPA, 20:5n-3] and DHA) content in
a cohort of elderly subjects were associated with faster cognitive decline than in those with high
n-3 FA erythrocyte content [
192
]. Similarly, in an elderly cohort, subjects within the lowest quartile
of erythrocyte DHA concentrations had poorer memory test performance than individuals in the
higher quartiles [
193
]. A positive correlation was observed between DHA intake and plasma PC-DHA
concentrations in an FHS Generation 1 study, and was associated with a 50% reduction of dementia risk
in this cohort [
178
]. Interestingly, in an intervention study of young women consuming 200 mg/day of
DHA, increasing choline intake from 480 mg/day to 930 mg/day for six weeks increased PC-DHA
concentrations in plasma and erythrocytes by 50% and 20%, respectively [
194
]. Conversely, plasma
PC-DHA concentrations dropped in subjects placed on a choline-deficient diet [
195
]. Together these
studies show that circulating PC-DHA levels are subject to regulation by the dietary supply of
DHA and choline. Moreover, EPA and DHA are transported across the blood-brain-barrier from
plasma to brain in the form of the lysophosphatidylcholines (LPC), LPC-EPA, and LPC-DHA, in
a process that is catalyzed by a specific transporter, major facilitator superfamily domain containing
2a (MFSD2A) [
196
199
] (Figure 3). Thus, plasma levels of these LPC species may govern the rate of
the supply of these essential fatty acids to brain, and there are indications of reduced plasma levels of
LPC associated with AD [
183
,
186
]. Intervention studies using polyunsaturated fatty acids or DHA to
treat dementia have been reviewed recently [
200
], and efficacy has been observed in some of those
studies. Not surprisingly, early intervention works better, and the response to treatment may be
attenuated in subjects with the APOE4 genotype [
201
,
202
]—the major genetic risk factor for AD [
203
].
Taken together, the evidence suggests that an adequate dietary supply of choline and DHA is necessary
to maintain plasma and brain PC-DHA levels, and may possibly help to slow the onset of cognitive
decline with aging, and potentially to delay or ameliorate the pathogenetic process in AD.
Nutrients 2017, 9, 815 8 of 22
reported as reduced in prodromal and/or frank AD [178,181–183,186,188]. Data obtained by studies
of erythrocyte membrane lipids further support these notions. Because erythrocytes live for an
average of 120 days, their lipid profiles reflect whole body lipid metabolism over several months
[189,190] as opposed to the snapshot view obtained from a plasma assay. In a study by Selley [191],
erythrocytes from AD patients had reductions in concentrations of PC of 23% and of PC-DHA of 60%
as compared to controls. Moreover, lower levels of erythrocyte phospholipid n-3 fatty acid
(eicosapentaenoic [EPA, 20:5n-3] and DHA) content in a cohort of elderly subjects were associated
with faster cognitive decline than in those with high n-3 FA erythrocyte content [192]. Similarly, in
an elderly cohort, subjects within the lowest quartile of erythrocyte DHA concentrations had poorer
memory test performance than individuals in the higher quartiles [193]. A positive correlation was
observed between DHA intake and plasma PC-DHA concentrations in an FHS Generation 1 study,
and was associated with a 50% reduction of dementia risk in this cohort [178]. Interestingly, in an
intervention study of young women consuming 200 mg/day of DHA, increasing choline intake from
480 mg/day to 930 mg/day for six weeks increased PC-DHA concentrations in plasma and
erythrocytes by 50% and 20%, respectively [194]. Conversely, plasma PC-DHA concentrations
dropped in subjects placed on a choline-deficient diet [195]. Together these studies show that
circulating PC-DHA levels are subject to regulation by the dietary supply of DHA and choline.
Moreover, EPA and DHA are transported across the blood-brain-barrier from plasma to brain in the
form of the lysophosphatidylcholines (LPC), LPC-EPA, and LPC-DHA, in a process that is catalyzed
by a specific transporter, major facilitator superfamily domain containing 2a (MFSD2A) [196–199]
(Figure 3). Thus, plasma levels of these LPC species may govern the rate of the supply of these
essential fatty acids to brain, and there are indications of reduced plasma levels of LPC associated
with AD [183,186]. Intervention studies using polyunsaturated fatty acids or DHA to treat dementia
have been reviewed recently [200], and efficacy has been observed in some of those studies. Not
surprisingly, early intervention works better, and the response to treatment may be attenuated in
subjects with the APOE4 genotype [201,202]—the major genetic risk factor for AD [203]. Taken
together, the evidence suggests that an adequate dietary supply of choline and DHA is necessary to
maintain plasma and brain PC-DHA levels, and may possibly help to slow the onset of cognitive
decline with aging, and potentially to delay or ameliorate the pathogenetic process in AD.
Figure 3. PC-DHA levels depend on nutrition, liver and brain synthesis by PEMT and transport of
LPC-DHA across the blood-brain barrier catalyzed by MFSD2A. Plasma PC levels and PC FA
molecular species (e.g., PC-DHA) depend on hepatic PC metabolism, the dietary supply of choline
and n-3 FA, including DHA, and PC and LPC flux between plasma and tissues (e.g., brain). Hepatic
PEMT activity is high and the liver produces large amounts of PC-DHA by methylating PE for the
needs of the entire organism. This PC-DHA is secreted by the liver into the circulation as a component
of lipoproteins. Brain PEMT activity is relatively low and neuronal and glial PEMT produces PC-
DHA to sustain local membranes. PC synthesis by PEMT requires three molecules of SAM that is
synthesized from the amino acid, methionine. In addition to PC, PEMT generates SAH that is
hydrolyzed to homocysteine. The latter can be converted back to methionine by two pathways: one
Figure 3.
PC-DHA levels depend on nutrition, liver and brain synthesis by PEMT and transport of
LPC-DHA across the blood-brain barrier catalyzed by MFSD2A. Plasma PC levels and PC FA molecular
species (e.g., PC-DHA) depend on hepatic PC metabolism, the dietary supply of choline and n-3 FA,
including DHA, and PC and LPC flux between plasma and tissues (e.g., brain). Hepatic PEMT activity
is high and the liver produces large amounts of PC-DHA by methylating PE for the needs of the entire
organism. This PC-DHA is secreted by the liver into the circulation as a component of lipoproteins.
Brain PEMT activity is relatively low and neuronal and glial PEMT produces PC-DHA to sustain
local membranes. PC synthesis by PEMT requires three molecules of SAM that is synthesized from the
Nutrients 2017,9, 815 9 of 23
amino acid, methionine. In addition to PC, PEMT generates SAH that is hydrolyzed to
homocysteine. The latter can be converted back to methionine by two pathways: one catalyzed by
betaine:homocysteine S-methyltransferase (BHMT) and another catalyzed by vitamin B12-requiring
5-methyltetrahydrofolate-homocysteine S-methyltransferase (MTR), in which methyltetrahydrofolate
is used as a methyl donor. Betaine is the product of enzymatic oxidation of choline. Thus, dietary
choline is used to produce PC directly and to convert homocysteine to methionine and subsequently
to SAM. In this fashion the methyl groups derived from dietary choline can be utilized by
PEMT to generate PC-DHA. Recent evidence indicates that the main source of brain DHA is
LPC-DHA—the circulating deacylated metabolite of PC-DHA. The transport of LPC-DHA from
plasma to the brain is catalyzed by MFSD2A. The blue arrows indicate flux and the black
arrows represent enzymatic pathways. Protein names are in red. Dietary DHA is primarily
stored in PE in tissues and only a small fraction is incorporated directly into PC. Homocysteine
can also be converted to cysteine via cystathionine in a transsulfuration pathway that includes
two vitamin B6-requiring enzymes, CBS and CTH. Abbreviations: BHMT, betaine:homocysteine
S-methyltransferase; CBS, cystathionine-beta-synthase; CTH, cystathionine gamma-lyase; DHA,
docosahexaenoic acid; FA,fatty acid; LPC, lysophosphatidylcholine; MFSD2A, major facilitator
superfamily domain containing 2a; MTR, 5-methyltetrahydrofolate-homocysteine S-methyltransferase;
PC, phosphatidylcholine; PE, phosphatidylethanolamine; PEMT, phosphatidylethanolamine
N-methyltransferase; SAH, S-adenosylhomocysteine; SAM, S-adenosylmethionine.
3. Choline Availability, Phosphatidylethanolamine N-methyltransferase, and Cognitive Ability
Most of the polyunsaturated PCs in mammals, including PC-DHA, are synthesized
by phosphatidylethanolamine N-methyltransferase (PEMT) [
195
,
204
207
], which methylates
phosphatidylethanolamine (PE) to generate PC using SAM as the methyl donor (Figure 3). The main
site of the PEMT-catalyzed synthesis of PC-DHA is liver [
195
,
204
206
], which secretes it into the
circulation as a component of very low density lipoproteins. PEMT activity in brain is relatively
low [
208
], and the polyunsaturated species of PC (including PC-EPA and PC-DHA) [
207
] that are
synthesized there are adequate for local needs only. PEMT activity in brain is higher during the
perinatal period and declines in adulthood [
209
]. The PEMT reaction consumes three molecules of
SAM for every PC molecule produced, and generates three molecules of S-adenosylhomocysteine
(SAH). SAH is an inhibitor of PEMT (reviewed in [
210
]) and so, for PEMT to be active, SAH
must be rapidly hydrolyzed to homocysteine and then remethylated to generate methionine and
subsequently, SAM. Alternatively, homocysteine may be catabolized to cysteine via pyridoxal
phosphate (vitamin B6)-dependent transsulfuration [
211
]. Some of the SAH-derived hepatic
homocysteine enters the circulation. This results in a quantitatively significant link between hepatic
PEMT activity and plasma levels of homocysteine [
212
]. High blood levels of homocysteine are
associated with high plasma levels of SAH [
213
,
214
], whereas low plasma SAM/SAH ratio strongly
correlates with low levels of plasma PC-DHA [
195
], and an increased risk of AD [
215
]. In 2002,
a prospective evaluation of dementia-free FHS Generation 1 subjects showed that elevations in plasma
homocysteine concentrations over eight years prior to the onset of clinical dementia predicted the
subsequent development of AD [
215
]. A meta-analysis confirmed these results [
216
]. In a study
of 29 AD patients and 26 controls, the high plasma SAH and homocysteine concentrations that
characterized the AD patients, were associated with reduced levels of erythrocyte PC-DHA [
191
].
There are two enzymatic pathways that cause the remethylation of homocysteine to methionine: one is
catalyzed by the vitamin B12-requiring 5-methyltetrahydrofolate-homocysteine S-methyltransferase
(MTR), in which methyltetrahydrofolate is used as a methyl donor, and the other is catalyzed by
betaine:homocysteine S-methyltransferase (BHMT) (reviewed in [
73
]). Betaine can be derived from the
diet [
2
] and it is also produced in the liver by choline dehydrogenase [
217
]. Thus, in this way, choline
is not the direct precursor of the PC headgroup, but rather, once oxidized to form betaine, donates
a methyl group to homocysteine to form methionine, which is then converted to SAM (Figure 3).
This SAM can be used by PEMT to generate the DHA molecular species of PC. In sum, dietary choline
Nutrients 2017,9, 815 10 of 23
and its metabolite betaine, as well as folate and vitamins B6 and B12, via regulation of homocysteine
and methionine levels, play central roles in the maintenance of adequate levels of PC-DHA in liver,
plasma, and brain, and this in turn may moderate the risk of AD in human populations.
The importance of PEMT in cognitive function is further underscored by evidence that
polymorphisms in PEMT affecting activity may be related to AD risk. The SNP rs7946 G523A causing
the amino acid substitution V175M is associated with increased risk of AD in a study of a Chinese
cohort [
218
]. The association was particularly significant in women and individuals who are not
carriers of the APOE4 gene.
In vitro
, the PEMT
175M
enzyme, encoded by the A allele associated with
AD, is 35% less active than the PEMT
175V
isoform [
219
], suggesting that carriers of the A allele may
have a defect in PC-DHA production. Given that AD is more common in women than in men (based
on FHS data, it was estimated that after the age of 65, one in five women and one in ten men are
destined to develop AD [
220
]), the female-specific association between the rs7946 PEMT SNP and
AD is particularly intriguing because, depending on another PEMT SNP (rs12325817 present in an
intron), PEMT expression can be modulated by estrogen [
195
,
219
,
221
224
]. In individuals with the
rs12325817 G allele, hepatic PEMT expression is induced by estrogen whereas in persons with the
C allele this response is absent [
223
]. It has been proposed that during pregnancy and lactation the
estrogen-induced PEMT generates PC and choline necessary for the normal development of the fetus
and baby [
222
]. Indeed, young women on choline-deficient diets are resistant to liver and muscle
dysfunction because of the high activity of their estrogen-regulated PEMT, which produces choline
de novo [
222
]. In contrast, these symptoms are typically seen in men and postmenopausal women on
such diets [
6
,
225
]. Theseobservations reinforce earlier studies in animals that showed that levels of
PEMT in the brain are regulated by the dietary supply of choline in a sexually dimorphic fashion,
i.e., choline deficiency increases PEMT activity in brains of female, but not male, rats [
226
]. Thus,
the production of PC-DHA can be modulated by: (1) diet; (2) intrinsic PEMT activity determined
by its amino acid sequence encoded by specific PEMT alleles; and (3) sexually dimorphic regulation
of the amount of PEMT enzyme expressed in the liver (and possibly in brain [
226
]) due to PEMT
allele-specific responsiveness to estrogen. These data point to strong associations between dietary
intake of DHA and choline, brain PEMT activity, sex, and phenotypes associated with cognitive
impairment and AD.
Although the studies summarized in the preceding paragraphs underscore the potential benefits
of adequate dietary choline intake, less is known about the potential harms of excess choline
supplementation [
227
]. The addition of methylation pathway components such as folate, choline, and
B vitamins to certain food products as well as dietary supplements has coincided with an increased
incidence of diseases related to altered DNA methylation including cancer, autism spectrum disorders,
and some neurological disorders (reviewed in [
228
]). A prospective study of male health professionals
reported an increased risk of lethal prostate cancer in subjects in the highest quintile of choline
consumption, even after adjusting for the presence of other nutrients that could increase cancer
risk [
229
]. In contrast, several studies reported that high choline intake was associated with reduced
incidence of breast [
9
], colorectal [
230
] and liver [
13
] cancer. It is clear that more studies in humans will
be necessary to refine our understanding of what constitutes optimal choline intake at various stages of
life, and how this may be affected by polymorphisms in the genes responsible for choline metabolism.
4. Conclusions
High choline intake during gestation and the early postnatal period has been shown to enhance
cognitive performance in childhood, adulthood and into old age in multiple animal models and in
some human studies. Moreover, choline is neuroprotective in a variety of experimental models of
neuronal damage. Choline intake in adulthood may also be critical for normal cognitive function
in people. The maternal choline supply during pregnancy modifies fetal DNA [
78
,
231
] and histone
methylation [
232
], implicating an epigenomic mechanism in these long-term effects. While these
epigenomic mechanisms may also operate in the adult, the effects of dietary choline both during
Nutrients 2017,9, 815 11 of 23
development and in the adult brain may also be mediated, at least in part, by an influence on the
peripheral and central metabolism of polyunsaturated species of PC. Taken together, the available
evidence strongly supports the notion that adequate choline intake during pregnancy, and throughout
life, is an important determinant of brain development, cognitive performance in the adult, and
resistance to cognitive decline associated with aging and neurodegenerative disease.
Acknowledgments:
Some of the studies reviewed here were supported by N.I.H. grants AG009525 and CA120488
to J.K.B. and a grant from the Simons Foundation to T.J.M.
Author Contributions: J.K.B., B.E.S. and T.J.M. wrote the paper.
Conflicts of Interest: The authors declare no conflict of interest.
References
1.
Food and Nutrition Board. Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B
6
, Folate,
Vitamin B12, Panthotenic Acid, Biotin, and Cholin; National Academy Press: Washington, DC, USA, 1998.
2.
Patterson, K.Y.; Bhagwat, A.S.; Williams, J.R.; Howe, J.C.; Holden, J.M.; Zeisel, S.H.; Da Costa, C.A.;
Mar, H. USDA Database for the Choline Content of Common Foods. Release Two. Available online:
http://www.ars.usda.gov/Services/docs.htm?docid=6232 (accessed on 26 August 2017).
3.
Garner, S.C.; Mar, M.H.; Zeisel, S.H. Choline distribution and metabolism in pregnant rats and fetuses are
influenced by the choline content of the maternal diet. J. Nutr. 1995,125, 2851–2858. [PubMed]
4.
Holmes-McNary, M.Q.; Cheng, W.L.; Mar, M.H.; Fussell, S.; Zeisel, S.H. Choline and choline esters in human
and rat milk and in infant formulas. Am. J. Clin. Nutr. 1996,64, 572–576. [PubMed]
5. Zeisel, S.H.; Char, D.; Sheard, N.F. Choline, phosphatidylcholine and sphingomyelin in human and bovine
milk and infant formulas. J. Nutr. 1986,116, 50–58. [PubMed]
6.
Zeisel, S.H.; Da Costa, K.-A.; Franklin, P.D.; Alexander, E.A.; Lamont, J.T.; Sheard, N.F.; Beiser, A. Choline,
an essential nutrient for humans. FASEB J. 1991,5, 2093–2098. [CrossRef]
7.
Da Costa, K.A.; Badea, M.; Fischer, L.M.; Zeisel, S.H. Elevated serum creatine phosphokinase in
choline-deficient humans: Mechanistic studies in C2C12 mouse myoblasts. Am. J. Clin. Nutr.
2004
,80,
163–170. [PubMed]
8.
Da Costa, K.A.; Niculescu, M.D.; Craciunescu, C.N.; Fischer, L.M.; Zeisel, S.H. Choline deficiency increases
lymphocyte apoptosis and DNA damage in humans. Am. J. Clin. Nutr. 2006,84, 88–94. [PubMed]
9.
Xu, X.; Gammon, M.D.; Zeisel, S.H.; Lee, Y.L.; Wetmur, J.G.; Teitelbaum, S.L.; Bradshaw, P.T.; Neugut, A.I.;
Santella, R.M.; Chen, J. Choline metabolism and risk of breast cancer in a population-based study. FASEB J.
2008,22, 2045–2052. [CrossRef] [PubMed]
10.
Ibiebele, T.I.; Hughes, M.C.; Pandeya, N.; Zhao, Z.; Montgomery, G.; Hayward, N.; Green, A.C.;
Whiteman, D.C.; Webb, P.M. High intake of folate from food sources is associated with reduced risk of
esophageal cancer in an Australian population. J. Nutr. 2011,141, 274–283. [CrossRef] [PubMed]
11.
Ying, J.; Rahbar, M.H.; Hallman, D.M.; Hernandez, L.M.; Spitz, M.R.; Forman, M.R.; Gorlova, O.Y. Associations
between dietary intake of choline and betaine and lung cancer risk. PLoS ONE 2013,8, e54561.
12.
Zhang, C.X.; Pan, M.X.; Li, B.; Wang, L.; Mo, X.F.; Chen, Y.M.; Lin, F.Y.; Ho, S.C. Choline and betaine intake is
inversely associated with breast cancer risk: A two-stage case-control study in China. Cancer Sci. 2013,104,
250–258. [CrossRef] [PubMed]
13.
Zhou, R.F.; Chen, X.L.; Zhou, Z.G.; Zhang, Y.J.; Lan, Q.Y.; Liao, G.C.; Chen, Y.M.; Zhu, H.L. Higher dietary
intakes of choline and betaine are associated with a lower risk of primary liver cancer: A case-control study.
Sci. Rep. 2017,7, 679. [CrossRef] [PubMed]
14. Zeisel, S. Choline, Other Methyl-Donors and Epigenetics. Nutrients 2017,9, 445. [CrossRef] [PubMed]
15.
Meck, W.H.; Williams, C.L. Simultaneous temporal processing is sensitive to prenatal choline availability in
mature and aged rats. Neuroreport 1997,8, 3045–3051. [CrossRef] [PubMed]
16.
Meck, W.H.; Williams, C.L. Metabolic imprinting of choline by its availability during gestation: Implications
for memory and attentional processing across the lifespan. Neurosci. Biobehav. Rev.
2003
,27, 385–399.
[CrossRef]
Nutrients 2017,9, 815 12 of 23
17.
Meck, W.H.; Williams, C.L.; Cermak, J.M.; Blusztajn, J.K. Developmental periods of choline sensitivity
provide an ontogenetic mechanism for regulating memory capacity and age-related dementia.
Front. Integr. Neurosci. 2007,1, 7. [CrossRef] [PubMed]
18.
Yang, Y.; Liu, Z.; Cermak, J.M.; Tandon, P.; Sarkisian, M.R.; Stafstrom, C.F.; Neill, J.C.; Blusztajn, J.K.;
Holmes, G.L. Protective effects of prenatal choline supplementation on seizure-induced memory impairment.
J. Neurosci. 2000,20, RC109. [PubMed]
19.
Holmes, G.L.; Yang, Y.; Liu, Z.; Cermak, J.M.; Sarkisian, M.R.; Stafstrom, C.E.; Neill, J.C.; Blusztajn, J.K.
Seizure-induced memory impairment is reduced by choline supplementation before or after status
epilepticus. Epilepsy Res. 2002,48, 3–13. [CrossRef]
20.
Glenn, M.J.; Kirby, E.D.; Gibson, E.M.; Wong-Goodrich, S.J.; Mellott, T.J.; Blusztajn, J.K.; Williams, C.L.
Age-related declines in exploratory behavior and markers of hippocampal plasticity are attenuated by
prenatal choline supplementation in rats. Brain Res. 2008,1237, 110–123. [CrossRef] [PubMed]
21.
Wong-Goodrich, S.J.; Mellott, T.J.; Liu, B.; Blusztajn, J.K.; Williams, C.L. Water maze experience and prenatal
choline supplementation differentially promote long-term hippocampal recovery from seizures in adulthood.
Hippocampus 2011,21, 584–608. [CrossRef] [PubMed]
22.
Thomas, J.D.; La Fiette, M.H.; Quinn, V.R.; Riley, E.P. Neonatal choline supplementation ameliorates the
effects of prenatal alcohol exposure on a discrimination learning task in rats. Neurotoxicol. Teratol.
2000
,22,
703–711. [CrossRef]
23.
Thomas, J.D.; Biane, J.S.; O’Bryan, K.A.; O’Neill, T.M.; Dominguez, H.D. Choline supplementation following
third-trimester-equivalent alcohol exposure attenuates behavioral alterations in rats. Behav. Neurosci.
2007
,
121, 120–130. [CrossRef] [PubMed]
24.
Ryan, S.H.; Williams, J.K.; Thomas, J.D. Choline supplementation attenuates learning deficits associated with
neonatal alcohol exposure in the rat: Effects of varying the timing of choline administration. Brain Res.
2008
,
1237, 91–100. [CrossRef] [PubMed]
25.
Thomas, J.D.; Tran, T.D. Choline supplementation mitigates trace, but not delay, eyeblink conditioning
deficits in rats exposed to alcohol during development. Hippocampus
2011
,22, 619–630. [CrossRef] [PubMed]
26.
Otero, N.K.; Thomas, J.D.; Saski, C.A.; Xia, X.; Kelly, S.J. Choline Supplementation and DNA Methylation
in the Hippocampus and Prefrontal Cortex of Rats Exposed to Alcohol during Development. Alcohol. Clin.
Exp. Res. 2012,36, 1701–1709. [CrossRef] [PubMed]
27.
Schneider, R.D.; Thomas, J.D. Adolescent Choline Supplementation Attenuates Working Memory Deficits in
Rats Exposed to Alcohol During the Third Trimester Equivalent. Alcohol. Clin. Exp. Res.
2016
,40, 897–905.
[CrossRef] [PubMed]
28.
Nag, N.; Berger-Sweeney, J.E. Postnatal dietary choline supplementation alters behavior in a mouse model
of Rett syndrome. Neurobiol. Dis. 2007,26, 473–480. [CrossRef] [PubMed]
29.
Nag, N.; Mellott, T.J.; Berger-Sweeney, J.E. Effects of postnatal dietary choline supplementation on motor
regional brain volume and growth factor expression in a mouse model of Rett syndrome. Brain Res.
2008
,
1237, 101–109. [CrossRef] [PubMed]
30.
Ricceri, L.; De Filippis, B.; Fuso, A.; Laviola, G. Cholinergic hypofunction in MeCP2–308 mice: Beneficial
neurobehavioural effects of neonatal choline supplementation. Behav. Brain Res.
2011
,221, 623–629.
[CrossRef] [PubMed]
31.
Ricceri, L.; De Filippis, B.; Laviola, G. Rett syndrome treatment in mouse models: Searching for effective
targets and strategies. Neuropharmacology 2013,68, 106–115. [CrossRef] [PubMed]
32.
Moon, J.; Chen, M.; Gandhy, S.U.; Strawderman, M.; Levitsky, D.A.; Maclean, K.N.; Strupp, B.J. Perinatal
choline supplementation improves cognitive functioning and emotion regulation in the Ts65Dn mouse
model of Down syndrome. Behav. Neurosci. 2010,124, 346–361. [CrossRef] [PubMed]
33.
Kelley, C.M.; Powers, B.E.; Velazquez, R.; Ash, J.A.; Ginsberg, S.D.; Strupp, B.J.; Mufson, E.J. Maternal choline
supplementation differentially alters the basal forebrain cholinergic system of young-adult Ts65Dn and
disomic mice. J. Comp. Neurol. 2014,522, 1390–1410. [CrossRef] [PubMed]
34.
Strupp, B.J.; Powers, B.E.; Velazquez, R.; Ash, J.A.; Kelley, C.M.; Alldred, M.J.; Strawderman, M.;
Caudill, M.A.; Mufson, E.J.; Ginsberg, S.D. Maternal Choline Supplementation: A Potential Prenatal
Treatment for Down Syndrome and Alzheimer’s Disease. Curr. Alzheimer Res.
2016
,13, 97–106. [CrossRef]
[PubMed]
Nutrients 2017,9, 815 13 of 23
35.
Velazquez, R.; Ash, J.A.; Powers, B.E.; Kelley, C.M.; Strawderman, M.; Luscher, Z.I.; Ginsberg, S.D.;
Mufson, E.J.; Strupp, B.J. Maternal choline supplementation improves spatial learning and adult hippocampal
neurogenesis in the Ts65Dn mouse model of Down syndrome. Neurobiol. Dis.
2013
,58, 92–101. [CrossRef]
[PubMed]
36.
Powers, B.E.; Kelley, C.M.; Velazquez, R.; Ash, J.A.; Strawderman, M.S.; Alldred, M.J.; Ginsberg, S.D.;
Mufson, E.J.; Strupp, B.J. Maternal choline supplementation in a mouse model of Down syndrome: Effects
on attention and nucleus basalis/substantia innominata neuron morphology in adult offspring. Neuroscience
2017,340, 501–514. [CrossRef] [PubMed]
37.
Ash, J.A.; Velazquez, R.; Kelley, C.M.; Powers, B.E.; Ginsberg, S.D.; Mufson, E.J.; Strupp, B.J. Maternal choline
supplementation improves spatial mapping and increases basal forebrain cholinergic neuron number and
size in aged Ts65Dn mice. Neurobiol. Dis. 2014,70, 32–42. [CrossRef] [PubMed]
38.
Kelley, C.M.; Ash, J.A.; Powers, B.E.; Velazquez, R.; Alldred, M.J.; Ikonomovic, M.D.; Ginsberg, S.D.;
Strupp, B.J.; Mufson, E.J. Effects of Maternal Choline Supplementation on the Septohippocampal Cholinergic
System in the Ts65Dn Mouse Model of Down Syndrome. Curr. Alzheimer Res.
2016
,13, 84–96. [CrossRef]
[PubMed]
39.
Jadavji, N.M.; Emmerson, J.T.; MacFarlane, A.J.; Willmore, W.G.; Smith, P.D. B-vitamin and choline
supplementation increases neuroplasticity and recovery after stroke. Neurobiol. Dis.
2017
,103, 89–100.
[CrossRef] [PubMed]
40.
Borges, A.A.; El-Batah, P.N.; Yamashita, L.F.; Santana Ados, S.; Lopes, A.C.; Freymuller-Haapalainen, E.;
Coimbra, C.G.; Sinigaglia-Coimbra, R. Neuroprotective effect of oral choline administration after global
brain ischemia in rats. Nutr. Neurosci. 2015,18, 265–274. [CrossRef] [PubMed]
41.
Shaw, G.M.; Carmichael, S.L.; Yang, W.; Selvin, S.; Schaffer, D.M. Periconceptional dietary intake of choline
and betaine and neural tube defects in offspring. Am. J. Epidemiol.
2004
,160, 102–109. [CrossRef] [PubMed]
42.
Carmichael, S.L.; Witte, J.S.; Shaw, G.M. Nutrient pathways and neural tube defects: A semi-Bayesian
hierarchical analysis. Epidemiology 2009,20, 67–73. [CrossRef] [PubMed]
43.
Carmichael, S.L.; Yang, W.; Shaw, G.M. Periconceptional nutrient intakes and risks of neural tube defects in
California. Birth Defects Res. 2010,88, 670–678. [CrossRef] [PubMed]
44.
Lavery, A.M.; Brender, J.D.; Zhao, H.; Sweeney, A.; Felkner, M.; Suarez, L.; Canfield, M.A. Dietary intake
of choline and neural tube defects in Mexican Americans. Birth Defects Res.
2014
,100, 463–471. [CrossRef]
[PubMed]
45.
Poly, C.; Massaro, J.M.; Seshadri, S.; Wolf, P.A.; Cho, E.; Krall, E.; Jacques, P.F.; Au, R. The relation of dietary
choline to cognitive performance and white-matter hyperintensity in the Framingham Offspring Cohort.
Am. J. Clin. Nutr. 2011,94, 1584–1591. [CrossRef] [PubMed]
46.
Parnetti, L.; Mignini, F.; Tomassoni, D.; Traini, E.; Amenta, F. Cholinergic precursors in the treatment of
cognitive impairment of vascular origin: Ineffective approaches or need for re-evaluation? J. Neurol. Sci.
2007,257, 264–269. [CrossRef] [PubMed]
47.
Meck, W.H.; Smith, R.A.; Williams, C.L. Pre- and postnatal choline supplementation produces long-term
facilitation of spatial memory. Dev. Psychobiol. 1998,21, 339–353. [CrossRef] [PubMed]
48.
Schenk, F.; Brandner, C. Indirect effect of peri- and postnatal choline treatment on place-learning abilities in
rat. Psychobiology 1995,23, 302–313.
49.
Jones, J.P.; Meck, W.H.; Williams, C.L.; Wilson, W.A.; Swartzwelder, H.S. Choline availability to the
developing rat fetus alters adult hippocampal long-term potentiation. Dev. Brain Res.
1999
,118, 159–167.
[CrossRef]
50.
Tees, R.C.; Mohammadi, E. The effects of neonatal choline dietary supplementation on adult spatial and
configural learning and memory in rats. Dev. Psychobiol. 1999,35, 226–240. [CrossRef]
51.
Mellott, T.J.; Williams, C.L.; Meck, W.H.; Blusztajn, J.K. Prenatal choline supplementation advances
hippocampal development and enhances MAPK and CREB activation. FASEB J.
2004
,18, 545–547. [CrossRef]
[PubMed]
52.
Buhusi, C.V.; Lamoureux, J.A.; Meck, W.H. Prenatal choline supplementation increases sensitivity to
contextual processing of temporal information. Brain Res. 2008,1237, 204–213. [CrossRef] [PubMed]
53.
Cheng, R.K.; MacDonald, C.J.; Williams, C.L.; Meck, W.H. Prenatal choline supplementation alters the
timing, emotion, and memory performance (TEMP) of adult male and female rats as indexed by differential
reinforcement of low-rate schedule behavior. Learn. Mem. 2008,15, 153–162. [CrossRef] [PubMed]
Nutrients 2017,9, 815 14 of 23
54.
Castro, C.A.; Rudy, J.W. Early-life malnutrition selectively retards the development of distal- but not
proximal-cue navigation. Dev. Psychobiol. 1987,20, 521–537. [CrossRef] [PubMed]
55.
Boeke, C.E.; Gillman, M.W.; Hughes, M.D.; Rifas-Shiman, S.L.; Villamor, E.; Oken, E. Choline intake during
pregnancy and child cognition at age 7 years. Am. J. Epidemiol. 2013,177, 1338–1347. [CrossRef] [PubMed]
56.
Albright, C.D.; Friedrich, C.B.; Brown, E.C.; Mar, M.H.; Zeisel, S.H. Maternal dietary choline availability alters
mitosis, apoptosis and the localization of TOAD-64 protein in the developing fetal rat septum. Dev. Psychobiol.
1999,115, 123–129. [CrossRef]
57.
Craciunescu, C.N.; Albright, C.D.; Mar, M.H.; Song, J.; Zeisel, S.H. Choline availability during embryonic
development alters progenitor cell mitosis in developing mouse hippocampus. J. Nutr.
2003
,133, 3614–3618.
[PubMed]
58.
Clelland, C.D.; Choi, M.; Romberg, C.; Clemenson, G.D., Jr.; Fragniere, A.; Tyers, P.; Jessberger, S.; Saksida, L.M.;
Barker, R.A.; Gage, F.H.; et al. A functional role for adult hippocampal neurogenesis in spatial pattern
separation. Science 2009,325, 210–213. [CrossRef] [PubMed]
59.
Kitamura, T.; Saitoh, Y.; Takashima, N.; Murayama, A.; Niibori, Y.; Ageta, H.; Sekiguchi, M.; Sugiyama, H.;
Inokuchi, K. Adult neurogenesis modulates the hippocampus-dependent period of associative fear memory.
Cell 2009,139, 814–827. [CrossRef] [PubMed]
60.
Goncalves, J.T.; Schafer, S.T.; Gage, F.H. Adult Neurogenesis in the Hippocampus: From Stem Cells to
Behavior. Cell 2016,167, 897–914. [CrossRef] [PubMed]
61.
Glenn, M.J.; Gibson, E.M.; Kirby, E.D.; Mellott, T.J.; Blusztajn, J.K.; Williams, C.L. Prenatal choline availability
modulates hippocampal neurogenesis and neurogenic responses to enriching experiences in adult female
rats. Eur. J. Neurosci. 2007,25, 2473–2482. [CrossRef] [PubMed]
62.
Mellott, T.J.; Huleatt, O.M.; Shade, B.N.; Pender, S.M.; Liu, Y.B.; Slack, B.E.; Blusztajn, J.K. Perinatal choline
supplementation reduces amyloidosis and increases choline acetyltransferae expression in the hippocampus
of the APPswePS1dE9 Alzheimer’s disease model mice. PLoS ONE 2017,12, e0170450.
63.
Sandstrom, N.J.; Loy, R.; Williams, C.L. Prenatal choline supplementation increases NGF levels in the
hippocampus and frontal cortex of young and adult rats. Brain Res. 2002,947, 9–16. [CrossRef]
64.
Mellott, T.J.; Follettie, M.T.; Diesl, V.; Hill, A.A.; Lopez-Coviella, I.; Blusztajn, J.K. Prenatal choline availability
modulates hippocampal and cerebral cortical gene expression. FASEB J.
2007
,21, 1311–1323. [CrossRef]
[PubMed]
65.
Napoli, I.; Blusztajn, J.K.; Mellott, T.J. Prenatal choline supplementation in rats increases the expression of
IGF2 and its receptor IGF2R and enhances IGF2-induced acetylcholine release in hippocampus and frontal
cortex. Brain Res. 2008,1237, 124–135. [CrossRef] [PubMed]
66.
Williams, C.L.; Meck, W.H.; Heyer, D.; Loy, R. Hypertrophy of basal forebrain neurons and enhanced
visuospatial memory in perinatally choline-supplemented rats. Brain Res. 1998,794, 225–238. [CrossRef]
67.
Fibiger, H.C. Cholinergic mechanisms in learning, memory and dementia: A review of recent evidence.
Trends Neurosci. 1991,14, 220–223. [CrossRef]
68.
Sarter, M.; Parikh, V. Choline transporters, cholinergic transmission and cognition. Nat. Rev. Neurosci.
2005
,
6, 48–56. [CrossRef] [PubMed]
69.
Cermak, J.M.; Holler, T.; Jackson, D.A.; Blusztajn, J.K. Prenatal availability of choline modifies development
of the hippocampal cholinergic system. FASEB J. 1998,12, 349–357. [PubMed]
70.
Sweatt, J.D. The neuronal MAP kinase cascade: A biochemical signal integration system subserving synaptic
plasticity and memory. J. Neurochem. 2001,76, 1–10. [CrossRef] [PubMed]
71. Nicoll, R.A. A Brief History of Long-Term Potentiation. Neuron 2017,93, 281–290. [CrossRef] [PubMed]
72.
Pyapali, G.K.; Turner, D.A.; Williams, C.L.; Meck, W.H.; Swartzwelder, H.S. Prenatal dietary choline
supplementation decreases the threshold for induction of long-term potentiation in young adult rats.
J. Neurophysiol. 1998,79, 1790–1796. [PubMed]
73.
Blusztajn, J.K.; Mellott, T.J. Neuroprotective actions of perinatal choline nutrition. Clin. Chem. Lab. Med.
2013,51, 591–599. [CrossRef] [PubMed]
74.
Jones, P.A. Functions of DNA methylation: Islands, start sites, gene bodies and beyond. Nat. Rev.
2012
,13,
484–492. [CrossRef] [PubMed]
75.
Jones, P.A.; Liang, G. Rethinking how DNA methylation patterns are maintained. Nat. Rev.
2009
,10, 805–811.
[CrossRef] [PubMed]
Nutrients 2017,9, 815 15 of 23
76.
Chen, Z.X.; Riggs, A.D. DNA methylation and demethylation in mammals. J. Biol. Chem.
2011
,286,
18347–18353. [CrossRef] [PubMed]
77.
Blusztajn, J.K.; Mellott, T.J. Choline nutrition programs brain development via DNA and histone methylation.
Cent. Nerv. Syst. Agents Med. Chem. 2012,12, 82–94. [CrossRef] [PubMed]
78.
Kovacheva, V.P.; Mellott, T.J.; Davison, J.M.; Wagner, N.; Lopez-Coviella, I.; Schnitzler, A.C.; Blusztajn, J.K.
Gestational choline deficiency causes global and Igf2 gene DNA hypermethylation by up-regulation of
Dnmt1 expression. J. Biol. Chem. 2007,282, 31777–31788. [CrossRef] [PubMed]
79.
Lopes, S.; Lewis, A.; Hajkova, P.; Dean, W.; Oswald, J.; Forne, T.; Murrell, A.; Constancia, M.; Bartolomei, M.;
Walter, J.; et al. Epigenetic modifications in an imprinting cluster are controlled by a hierarchy of DMRs
suggesting long-range chromatin interactions. Hum. Mol. Genet. 2003,12, 295–305. [CrossRef] [PubMed]
80.
Chen, W.G.; Chang, Q.; Lin, Y.X.; Meissner, A.; West, A.E.; Griffith, E.C.; Jaenisch, R.; Greenberg, M.E.
Derepression of BDNF transcription involves calcium-dependent phosphorylation of MeCP2. Science
2003
,
302, 885–889. [CrossRef] [PubMed]
81.
Martinowich, K.; Hattori, D.; Wu, H.; Fouse, S.; He, F.; Hu, Y.; Fan, G.P.; Sun, Y.E. DNA methylation-related
chromatin remodeling in activity-dependent Bdnf gene regulation. Science
2003
,302, 890–893. [CrossRef]
[PubMed]
82.
Levenson, J.M.; Roth, T.L.; Lubin, F.D.; Miller, C.A.; Huang, I.C.; Desai, P.; Malone, L.M.; Sweatt, J.D. Evidence
that DNA (cytosine-5) methyltransferase regulates synaptic plasticity in the hippocampus. J. Biol. Chem.
2006,281, 15763–15773. [CrossRef] [PubMed]
83.
Nelson, E.D.; Kavalali, E.T.; Monteggia, L.M. Activity-dependent suppression of miniature
neurotransmission through the regulation of DNA methylation. J. Neurosci.
2008
,28, 395–406. [CrossRef]
[PubMed]
84.
Yossifoff, M.; Kisliouk, T.; Meiri, N. Dynamic changes in DNA methylation during thermal control
establishment affect CREB binding to the brain-derived neurotrophic factor promoter. Eur. J. Neurosci.
2008,28, 2267–2277. [CrossRef] [PubMed]
85.
Miller, C.A.; Sweatt, J.D. Covalent modification of DNA regulates memory formation. Neuron
2007
,53,
857–869. [CrossRef] [PubMed]
86.
Lubin, F.D.; Roth, T.L.; Sweatt, J.D. Epigenetic regulation of BDNF gene transcription in the consolidation of
fear memory. J. Neurosci. 2008,28, 10576–10586. [CrossRef] [PubMed]
87.
Feng, J.; Zhou, Y.; Campbell, S.L.; Le, T.; Li, E.; Sweatt, J.D.; Silva, A.J.; Fan, G. Dnmt1 and Dnmt3a maintain
DNA methylation and regulate synaptic function in adult forebrain neurons. Nat. Neurosci.
2010
,13, 423–430.
[CrossRef] [PubMed]
88.
Webb, W.M.; Sanchez, R.G.; Perez, G.; Butler, A.A.; Hauser, R.M.; Rich, M.C.; O’Bierne, A.L.; Jarome, T.J.;
Lubin, F.D. Dynamic association of epigenetic H3K4me3 and DNA 5hmC marks in the dorsal hippocampus
and anterior cingulate cortex following reactivation of a fear memory. Neurobiol. Learn. Mem.
2017
,142,
66–78. [CrossRef] [PubMed]
89.
Chen, R.; Zhang, Q.; Duan, X.; York, P.; Chen, G.D.; Yin, P.; Zhu, H.; Xu, M.; Chen, P.; Wu, Q.; et al.
The 5-Hydroxymethylcytosine (5hmC) Reader UHRF2 Is Required for Normal Levels of 5hmC in Mouse
Adult Brain and Spatial Learning and Memory. J. Biol. Chem. 2017,292, 4533–4543. [CrossRef] [PubMed]
90.
Kennedy, A.J.; Rahn, E.J.; Paulukaitis, B.S.; Savell, K.E.; Kordasiewicz, H.B.; Wang, J.; Lewis, J.W.; Posey, J.;
Strange, S.K.; Guzman-Karlsson, M.C.; et al. Tcf4 Regulates Synaptic Plasticity, DNA Methylation, and
Memory Function. Cell Rep. 2016,16, 2666–2685. [CrossRef] [PubMed]
91.
Penner, M.R.; Parrish, R.R.; Hoang, L.T.; Roth, T.L.; Lubin, F.D.; Barnes, C.A. Age-related changes in Egr1
transcription and DNA methylation within the hippocampus. Hippocampus
2016
,26, 1008–1020. [CrossRef]
[PubMed]
92.
Halder, R.; Hennion, M.; Vidal, R.O.; Shomroni, O.; Rahman, R.U.; Rajput, A.; Centeno, T.P.; van Bebber, F.;
Capece, V.; Garcia Vizcaino, J.C.; et al. DNA methylation changes in plasticity genes accompany the
formation and maintenance of memory. Nat. Neurosci. 2016,19, 102–110. [PubMed]
93.
Roth, E.D.; Roth, T.L.; Money, K.M.; SenGupta, S.; Eason, D.E.; Sweatt, J.D. DNA methylation regulates
neurophysiological spatial representation in memory formation. Neuroepigenetics
2015
,2, 1–8. [CrossRef]
[PubMed]
94.
Morris, M.J.; Adachi, M.; Na, E.S.; Monteggia, L.M. Selective role for DNMT3a in learning and memory.
Neurobiol. Learn. Mem. 2014,115, 30–37. [CrossRef] [PubMed]
Nutrients 2017,9, 815 16 of 23
95.
Rudenko, A.; Dawlaty, M.M.; Seo, J.; Cheng, A.W.; Meng, J.; Le, T.; Faull, K.F.; Jaenisch, R.; Tsai, L.H. Tet1 is
critical for neuronal activity-regulated gene expression and memory extinction. Neuron
2013
,79, 1109–1122.
[CrossRef] [PubMed]
96.
Kaas, G.A.; Zhong, C.; Eason, D.E.; Ross, D.L.; Vachhani, R.V.; Ming, G.L.; King, J.R.; Song, H.; Sweatt, J.D.
TET1 controls CNS 5-methylcytosine hydroxylation, active DNA demethylation, gene transcription, and
memory formation. Neuron 2013,79, 1086–1093. [CrossRef] [PubMed]
97.
Acharya, M.M.; Hattiangady, B.; Shetty, A.K. Progress in neuroprotective strategies for preventing epilepsy.
Prog. Neurobiol. 2008,84, 363–404. [CrossRef] [PubMed]
98.
Wong-Goodrich, S.J.; Mellott, T.J.; Glenn, M.J.; Blusztajn, J.K.; Williams, C.L. Prenatal choline
supplementation attenuates neuropathological response to status epilepticus in the adult rat hippocampus.
Neurobiol. Dis. 2008,30, 255–269. [CrossRef] [PubMed]
99.
Wong-Goodrich, S.J.; Glenn, M.J.; Mellott, T.J.; Blusztajn, J.K.; Meck, W.H.; Williams, C.L. Spatial memory
and hippocampal plasticity are differentially sensitive to the availability of choline in adulthood as a function
of choline supply in utero. Brain Res. 2008,1237, 153–166. [CrossRef] [PubMed]
100.
Parker, S.E.; Mai, C.T.; Canfield, M.A.; Rickard, R.; Wang, Y.; Meyer, R.E.; Anderson, P.; Mason, C.A.;
Collins, J.S.; Kirby, R.S.; et al. Updated National Birth Prevalence estimates for selected birth defects in the
United States, 2004–2006. Birth Defects Res. 2010,88, 1008–1016. [CrossRef] [PubMed]
101.
Karmiloff-Smith, A.; Al-Janabi, T.; D’Souza, H.; Groet, J.; Massand, E.; Mok, K.; Startin, C.; Fisher, E.; Hardy, J.;
Nizetic, D.; et al. The importance of understanding individual differences in Down syndrome. F1000Research
2016,5. [CrossRef] [PubMed]
102.
Reeves, R.H.; Irving, N.G.; Moran, T.H.; Wohn, A.; Kitt, C.; Sisodia, S.S.; Schmidt, C.; Bronson, R.T.;
Davisson, M.T. A mouse model for Down syndrome exhibits learning and behaviour deficits. Nat. Genet.
1995,11, 177–184. [CrossRef] [PubMed]
103.
Bourc
'
his, D.; Xu, G.L.; Lin, C.S.; Bollman, B.; Bestor, T.H. Dnmt3L and the establishment of maternal genomic
imprints. Science 2001,294, 2536–2539. [CrossRef] [PubMed]
104.
Chedin, F.; Lieber, M.R.; Hsieh, C.L. The DNA methyltransferase-like protein DNMT3L stimulates de novo
methylation by Dnmt3a. Proc. Natl. Acad. Sci. USA 2002,99, 16916–16921. [CrossRef] [PubMed]
105.
Mendioroz, M.; Do, C.; Jiang, X.; Liu, C.; Darbary, H.K.; Lang, C.F.; Lin, J.; Thomas, A.; Abu-Amero, S.;
Stanier, P.; et al. Trans effects of chromosome aneuploidies on DNA methylation patterns in human Down
syndrome and mouse models. Genome Biol. 2015,16, 263. [CrossRef] [PubMed]
106.
Do, C.; Xing, Z.; Yu, Y.E.; Tycko, B. Trans-acting epigenetic effects of chromosomal aneuploidies: Lessons
from Down syndrome and mouse models. Epigenomics 2017,9, 189–207. [CrossRef] [PubMed]
107.
Fasolino, M.; Zhou, Z. The Crucial Role of DNA Methylation and MeCP2 in Neuronal Function. Genes
2017
,
8, 141. [CrossRef] [PubMed]
108.
Ward, B.C.; Agarwal, S.; Wang, K.; Berger-Sweeney, J.; Kolodny, N.H. Longitudinal brain MRI study in
a mouse model of Rett Syndrome and the effects of choline. Neurobiol. Dis.
2008
,31, 110–119. [CrossRef]
[PubMed]
109.
Ward, B.C.; Kolodny, N.H.; Nag, N.; Berger-Sweeney, J.E. Neurochemical changes in a mouse model of Rett
syndrome: Changes over time and in response to perinatal choline nutritional supplementation. J. Neurochem.
2009,108, 361–371. [CrossRef] [PubMed]
110.
Stevens, K.E.; Adams, C.E.; Yonchek, J.; Hickel, C.; Danielson, J.; Kisley, M.A. Permanent improvement in
deficient sensory inhibition in DBA/2 mice with increased perinatal choline. Psychopharmacology
2008
,198,
413–420. [CrossRef] [PubMed]
111.
Singer, P.; Feldon, J.; Yee, B.K. Are DBA/2 mice associated with schizophrenia-like endophenotypes?
A behavioural contrast with C57BL/6 mice. Psychopharmacology 2009,206, 677–698. [PubMed]
112.
Greenwood, T.A.; Lazzeroni, L.C.; Calkins, M.E.; Freedman, R.; Green, M.F.; Gur, R.E.; Gur, R.C.; Light, G.A.;
Nuechterlein, K.H.; Olincy, A.; et al. Genetic assessment of additional endophenotypes from the Consortium
on the Genetics of Schizophrenia Family Study. Schizophr. Res. 2016,170, 30–40. [CrossRef] [PubMed]
113.
Singh, S.; Kumar, A.; Agarwal, S.; Phadke, S.R.; Jaiswal, Y. Genetic insight of schizophrenia: Past and future
perspectives. Gene 2014,535, 97–100. [CrossRef] [PubMed]
114.
Stevens, K.E.; Choo, K.S.; Stitzel, J.A.; Marks, M.J.; Adams, C.E. Long-term improvements in sensory
inhibition with gestational choline supplementation linked to alpha7 nicotinic receptors through studies in
Chrna7 null mutation mice. Brain Res. 2014,1552, 26–33. [CrossRef] [PubMed]
Nutrients 2017,9, 815 17 of 23
115.
Jankowsky, J.L.; Slunt, H.H.; Ratovitski, T.; Jenkins, N.A.; Copeland, N.G.; Borchelt, D.R. Co-expression of
multiple transgenes in mouse CNS: A comparison of strategies. Biomol. Eng. 2001,17, 157–165. [CrossRef]
116.
Götz, J.; Ittner, L.M. Animal models of Alzheimer’s disease and frontotemporal dementia. Nat. Rev.
2008
,9,
532–544. [CrossRef] [PubMed]
117.
Jankowsky, J.L.; Fadale, D.J.; Anderson, J.; Xu, G.M.; Gonzales, V.; Jenkins, N.A.; Copeland, N.G.; Lee, M.K.;
Younkin, L.H.; Wagner, S.L.; et al. Mutant presenilins specifically elevate the levels of the 42 residue
beta-amyloid peptide
in vivo
: Evidence for augmentation of a 42-specific gamma secretase. Hum. Mol. Genet.
2004,13, 159–170. [CrossRef] [PubMed]
118.
Savonenko, A.; Xu, G.M.; Melnikova, T.; Morton, J.L.; Gonzales, V.; Wong, M.P.; Price, D.L.; Tang, F.;
Markowska, A.L.; Borchelt, D.R. Episodic-like memory deficits in the APPswe/PS1dE9 mouse model
of Alzheimer’s disease: Relationships to beta-amyloid deposition and neurotransmitter abnormalities.
Neurobiol. Dis. 2005,18, 602–617. [CrossRef] [PubMed]
119.
Park, J.H.; Widi, G.A.; Gimbel, D.A.; Harel, N.Y.; Lee, D.H.; Strittmatter, S.M. Subcutaneous Nogo receptor
removes brain amyloid-beta and improves spatial memory in Alzheimer’s transgenic mice. J. Neurosci.
2006
,
26, 13279–13286. [CrossRef] [PubMed]
120.
O’Leary, T.P.; Brown, R.E. Visuo-spatial learning and memory deficits on the Barnes maze in the 16-month-old
APPswe/PS1dE9 mouse model of Alzheimer’s disease. Behav. Brain Res.
2009
,201, 120–127. [CrossRef]
[PubMed]
121.
Gimbel, D.A.; Nygaard, H.B.; Coffey, E.E.; Gunther, E.C.; Lauren, J.; Gimbel, Z.A.; Strittmatter, S.M. Memory
impairment in transgenic Alzheimer mice requires cellular prion protein. J. Neurosci.
2010
,30, 6367–6374.
[CrossRef] [PubMed]
122.
Kemppainen, S.; Rantamaki, T.; Jeronimo-Santos, A.; Lavasseur, G.; Autio, H.; Karpova, N.; Karkkainen, E.;
Staven, S.; Miranda, H.V.; Outeiro, T.F.; et al. Impaired TrkB receptor signaling contributes to memory
impairment in APP/PS1 mice. Neurobiol. Aging 2011,33, 1122.e23–1122.e39. [CrossRef] [PubMed]
123.
Perez, S.E.; Dar, S.; Ikonomovic, M.D.; Dekosky, S.T.; Mufson, E.J. Cholinergic forebrain degeneration in the
APPswe/PS1DeltaE9 transgenic mouse. Neurobiol. Dis. 2007,28, 3–15. [CrossRef] [PubMed]
124.
Machova, E.; Rudajev, V.; Smyckova, H.; Koivisto, H.; Tanila, H.; Dolezal, V. Functional cholinergic damage
develops with amyloid accumulation in young adult APPswe/PS1dE9 transgenic mice. Neurobiol. Dis.
2010
,
38, 27–35. [CrossRef] [PubMed]
125.
Payette, D.J.; Xie, J.; Guo, Q. Reduction in CHT1-mediated choline uptake in primary neurons from
presenilin-1 M146V mutant knock-in mice. Brain Res. 2007,1135, 12–21. [CrossRef] [PubMed]
126.
Goto, Y.; Niidome, T.; Hongo, H.; Akaike, A.; Kihara, T.; Sugimoto, H. Impaired muscarinic regulation
of excitatory synaptic transmission in the APPswe/PS1dE9 mouse model of Alzheimer’s disease.
Eur. J. Pharmacol. 2008,583, 84–91. [CrossRef] [PubMed]
127.
Nikolajsen, G.N.; Jensen, M.S.; West, M.J. Cholinergic axon length reduced by 300 meters in the brain of an
Alzheimer mouse model. Neurobiol. Aging 2011,32, 1927–1931. [CrossRef] [PubMed]
128.
Burke, R.M.; Norman, T.A.; Haydar, T.F.; Slack, B.E.; Leeman, S.E.; Blusztajn, J.K.; Mellott, T.J. BMP9
ameliorates amyloidosis and the cholinergic defect in a mouse model of Alzheimer’s disease. Proc. Natl.
Acad. Sci. USA 2013,110, 19567–19572. [CrossRef] [PubMed]
129.
Sanchez-Mut, J.V.; Aso, E.; Panayotis, N.; Lott, I.; Dierssen, M.; Rabano, A.; Urdinguio, R.G.; Fernandez, A.F.;
Astudillo, A.; Martin-Subero, J.I.; et al. DNA methylation map of mouse and human brain identifies target
genes in Alzheimer’s disease. Brain 2013,136, 3018–3027. [CrossRef] [PubMed]
130.
Gauthier, S.; Reisberg, B.; Zaudig, M.; Petersen, R.C.; Ritchie, K.; Broich, K.; Belleville, S.; Brodaty, H.;
Bennett, D.; Chertkow, H.; et al. Mild cognitive impairment. Lancet 2006,367, 1262–1270. [CrossRef]
131.
Haense, C.; Kalbe, E.; Herholz, K.; Hohmann, C.; Neumaier, B.; Krais, R.; Heiss, W.D. Cholinergic system
function and cognition in mild cognitive impairment. Neurobiol. Aging
2012
,33, 867–877. [CrossRef]
[PubMed]
132.
Sarter, M.; Bruno, J.P. Developmental origins of the age-related decline in cortical cholinergic function and
associated cognitive abilities. Neurobiol. Aging 2004,25, 1127–1139. [CrossRef] [PubMed]
133.
Whitehouse, P.J.; Price, D.L.; Struble, R.G.; Clark, A.W.; Coyle, J.T.; DeLong, M.R. Alzheimer’s disease and
senile dementia: Loss of neurons in the basal forebrain. Science 1982,215, 1237–1239. [CrossRef] [PubMed]
Nutrients 2017,9, 815 18 of 23
134.
Bowen, D.M.; Allen, S.J.; Benton, J.S.; Goodhardt, M.J.; Haan, E.A.; Palmer, A.M.; Sims, N.R.; Smith, C.C. T.;
Spillane, J.A.; Esiri, M.M.; et al. Biochemical assessment of serotonergic and cholinergic dysfunction and
cerebral atrophy in Alzheimer’s disease. J. Neurochem. 1983,41, 266–272. [CrossRef] [PubMed]
135.
Mufson, E.J.; Counts, S.E.; Perez, S.E.; Ginsberg, S.D. Cholinergic system during the progression of
Alzheimer’s disease: Therapeutic implications. Expert Rev. Neurother. 2008,8, 1703–1718. [PubMed]
136.
Grothe, M.; Heinsen, H.; Teipel, S.J. Atrophy of the cholinergic Basal forebrain over the adult age range and
in early stages of Alzheimer’s disease. Biol. Psychiatry 2012,71, 805–813. [CrossRef] [PubMed]
137.
Mellott, T.J.; Pender, S.M.; Burke, R.M.; Langley, E.A.; Blusztajn, J.K. IGF2 Ameliorates Amyloidosis, Increases
Cholinergic Marker Expression and Raises BMP9 and Neurotrophin Levels in the Hippocampus of the
APPswePS1dE9 Alzheimer’s Disease Model Mice. PLoS ONE 2014,9, e94287.
138.
Kamphuis, W.; Mamber, C.;